Continued Uptake of Novartis/Incyte's Jakafi Will Be the Greatest Driver of
Growth in the Myelofibrosis Therapy Market
However, Hydroxyurea Will Continue To Be Widely Used to Treat Constitutional
Symptoms of Myelofibrosis, According to Findings from Decision Resources
BURLINGTON, Mass., Jan. 31, 2013
BURLINGTON, Mass., Jan. 31, 2013 /PRNewswire/ --Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that, through 2021, the continued uptake of
Novartis/Incyte's recently launched JAK-2 inhibitor Jakafi (ruxolitinib) will
be the greatest driver of growth in the myelofibrosis therapy market in the
United States and Europe. Since only a small percentage of patients are
eligible for allogeneic stem-cell transplantation—the lone curative treatment
for myelofibrosis—the only care available for most patients is treatment of
disease symptoms. According to interviewed experts, the entry of ruxolitinib
is a significant advance in myelofibrosis treatment because they believe the
drug offers clear improvements in constitutional symptoms and reduces the
severe splenomegaly experienced by many patients, resulting in an overall
better quality of life.
(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )
According to Niche Markets and Rare Diseases: Myelofibrosis, JAK-2 inhibition
is the focus of considerable development activity in myelofibrosis and up to
five new JAK-2 inhibitors could launch for the disease through 2021. Clinical
trial data from long-term evaluation of myelofibrosis patients indicated that
ruxolitinib improves overall survival in addition to providing sustained
relief of constitutional symptoms—these recent analyses will likely accelerate
uptake of ruxolitinib and other JAK-2 inhibitors.
"The most promising emerging JAK-2 inhibitor—YM Biosciences' CYT-387—has
attracted interest from physicians because early phase trials have shown an
effect on anemia in addition to an effect on constitutional symptoms," said
Decision Resources Senior Vice President Cynthia Mundy, Ph.D. "Also, Gilead's
recent decision to acquire YM Biosciences to gain access to the drug suggests
Gilead expects CYT-387 to emerge as a formidable competitor to ruxolitinib and
that this agent could capture substantial market share."
The report also finds that, although interviewed experts are enthusiastic
about treatments that offer better management of myelofibrotic symptoms and
improvements in quality of life, they indicate they are likely to continue
using conventional treatment regimens in many of their patients, particularly
those assessed as having lower risk. As a result, although ruxolitinib will
experience significant adoption in the myelofibrosis market, hydroxyurea
(Bristol-Myers Squibb's Hydrea, generics) will continue to be widely used to
treat constitutional symptoms. Similarly, Celgene's emerging immunomodulator
pomalidomide will not displace use of the older, related drugs—Celgene's
Thalomid and Revlimid (lenolidomide).
Myelofibrosis is offered as part of Decision Resources' Niche Markets and Rare
Diseases service. Each report assesses opportunity in a select drug market
across the United States, France, Germany, Italy, Spain and the United
Kingdom. The report provides detailed coverage of patient populations, current
therapies, unmet needs and emerging therapies, and includes primary research
with country-specific thought leaders.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources
Contact: Christopher Comfort, Decision Resources, +1-781-993-2597,
Press spacebar to pause and continue. Press esc to stop.